Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Maertens

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 8, 2018
Improved survival after LTx-associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single-center experience and systematic reviewR C Minnee, S Fieuws, I Jochmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†S P Robinson, A Boumendil, H Finel, et al.
Bone Marrow Transplantation|October 27, 2015
Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working PartiesO Penack, G Tridello, J Hoek, et al.
The Journal of Antimicrobial Chemotherapy|December 29, 2020
The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosisM Cruciani, P L White, C Mengoli, et al.
Bone Marrow Transplantation|June 18, 2013
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMTS P Robinson, C Canals, J J Luang, et al.
Bone Marrow Transplantation|December 12, 2024
Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working PartyJ Brijs, C Peczynski, W Boreland, et al.
The Journal of Antimicrobial Chemotherapy|December 17, 2009
Forty-one recent cases of invasive zygomycosis from a global clinical registryM J G T Rüping, W J Heinz, A J Kindo, et al.
Bone Marrow Transplantation|September 15, 2015
In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?R Peffault de Latour, M Labopin, J Cornelissen, et al.
Bone Marrow Transplantation|November 8, 2016
Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMTM Robin, R Porcher, W Zinke-Cerwenka, et al.
Bone Marrow Transplantation|July 6, 2017
Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMTM Robin, R Porcher, W Zinke-Cerwenka, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 8, 2018
Improved survival after LTx-associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single-center experience and systematic reviewR C Minnee, S Fieuws, I Jochmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†S P Robinson, A Boumendil, H Finel, et al.
Bone Marrow Transplantation|October 27, 2015
Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working PartiesO Penack, G Tridello, J Hoek, et al.
The Journal of Antimicrobial Chemotherapy|December 29, 2020
The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosisM Cruciani, P L White, C Mengoli, et al.
Bone Marrow Transplantation|June 18, 2013
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMTS P Robinson, C Canals, J J Luang, et al.
Bone Marrow Transplantation|December 12, 2024
Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working PartyJ Brijs, C Peczynski, W Boreland, et al.
The Journal of Antimicrobial Chemotherapy|December 17, 2009
Forty-one recent cases of invasive zygomycosis from a global clinical registryM J G T Rüping, W J Heinz, A J Kindo, et al.
Bone Marrow Transplantation|September 15, 2015
In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?R Peffault de Latour, M Labopin, J Cornelissen, et al.
Bone Marrow Transplantation|November 8, 2016
Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMTM Robin, R Porcher, W Zinke-Cerwenka, et al.
Bone Marrow Transplantation|July 6, 2017
Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMTM Robin, R Porcher, W Zinke-Cerwenka, et al.
Pageof 9